Modified CC10 Protein Isoforms for Oxidative Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing secretoglobins, particularly CC10, undergo oxidative modifications during inflammatory responses that impair their anti-inflammatory and immunomodulatory functions, contributing to chronic lung diseases, and there is a lack of understanding of these modifications and their impact on biological activity.
Innovation Solution
Chemical modification of synthetic secretoglobins using reactive oxygen species (ROS), reactive nitrogen species (RNS), and enzymatic modification with myeloperoxidase or transglutaminase to alter or enhance their biological properties, including the formation of specific amino acid adducts and multimers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If secretoglobins undergo oxidative modifications during inflammatory responses, then they are exposed to ROS and RNS in the inflammatory environment, but their anti-inflammatory and immunomodulatory functions are impaired
Solution Approach 1:
The patent applies preliminary anti-action by pre-modifying secretoglobins with ROS and RNS under controlled conditions before therapeutic administration. This pre-modification creates oxidized isoforms that are resistant to further oxidative damage during inflammatory responses, thereby preserving their anti-inflammatory function rather than allowing harmful oxidative modifications to occur during treatment
Solution Approach 2:
The patent converts the harmful effect of oxidative modification into a beneficial property by deliberately exposing secretoglobins to ROS and RNS during production. This process generates specific oxidized amino acid adducts (such as carbonyl groups, nitrotyrosine, and chlorotyrosine) that enhance the protein's stability and anti-inflammatory activity, transforming what would normally be damaging modifications into therapeutic advantages
2Reliability
If chemical modification with ROS and RNS is applied to enhance biological activity, then anti-viral and anti-inflammatory properties are improved, but the complexity of production and characterization increases
Solution Approach 1:
The patent uses reactive oxygen species and reactive nitrogen species as intermediaries to mediate the modification of secretoglobins. These intermediaries (ROS such as hydroxyl radicals, peroxynitrite; RNS such as nitric oxide derivatives) facilitate the formation of specific amino acid adducts that enhance biological activity while allowing for controlled and reproducible modification processes
Solution Approach 2:
The patent applies parameter changes by systematically varying oxidation conditions (ROS/RNS concentration, exposure time, pH, temperature) to optimize the formation of beneficial oxidized isoforms. By controlling these parameters, the process achieves enhanced biological activity while managing production complexity through standardized protocols
3Manufacturing precision
If enzymatic modification with myeloperoxidase or transglutaminase is used, then specific amino acid adducts are formed to enhance function, but the manufacturing process becomes more complex
Solution Approach 1:
The patent applies self-service by utilizing endogenous enzymes (myeloperoxidase and transglutaminase) that naturally occur in inflammatory environments. These enzymes automatically catalyze the formation of specific amino acid adducts (such as tyrosine nitration by MPO and cross-linking by transglutaminase) without requiring external intervention, thereby enhancing manufacturing precision while simplifying the overall production process
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified secretoglobins exhibit enhanced anti-viral activity and inhibition of neutrophil migration, offering potential therapeutic benefits for inflammatory and respiratory conditions.
Implementation Method 1
chemical modification with ROS, reactive nitrogen species (RNS), and enzyme-catalyzed amino acid modification
Implementation Method 2
chemical modification with ROS, reactive nitrogen species (RNS), and enzyme-catalyzed amino acid modification
Implementation Method 3
enzyme catalyzed modification such as myeloperoxidase plus hydrogen peroxide
Implementation Method 4
enzyme catalyzed modification such as myeloperoxidase plus hydrogen peroxide
Implementation Method 5
transglutaminase catalyzed modification
Data Source
AI summary
Novel compositions of recombinant human CC10 protein have been generated by chemically modifying the pure protein in vitro. Several new synthetic preparations containing isoforms of chemically modified rhCC10 have been generated by processes that utilize reactive oxygen species and reactive nitrogen species. These preparations contain novel isoforms of rhCC10 which have been characterized with enhanced or altered biological properties compared to the unmodified protein. Preparations containing novel isoforms may be used as standards to identify and characterize naturally occurring isoforms of native CC10 protein from blood or urine and ultimately to measure new CC10-based biomarkers to assess patient disease status. These preparations may also be used to treat respiratory, autoimmune, inflammatory, and other medical conditions that are not effectively treated with the unmodified protein.